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Abstract
Background: Carpal tunnel syndrome is a common disorder, which can be treated with surgery
or conservative options. However, there is insufficient evidence and no consensus among
physicians with regard to the preferred treatment for carpal tunnel syndrome. Therefore, a
randomized controlled trial is conducted to compare the short- and long-term efficacy of surgery
and splinting in patients with carpal tunnel syndrome. An attempt is also made to avoid the
(methodological) limitations encountered in earlier trials on the efficacy of various treatment
options for carpal tunnel syndrome.
Methods: Patients of 18 years and older, with clinically and electrophysiologically confirmed
idiopathic carpal tunnel syndrome, are recruited by neurologists in 13 hospitals. Patients included
in the study are randomly allocated to either open carpal tunnel release or wrist splinting during
the night for at least 6 weeks. The primary outcomes are general improvement, waking up at night
and severity of symptoms (main complaint, night and daytime pain, paraesthesia and hypoesthesia).
Outcomes are assessed up to 18 months after randomization.
Background
CTS is a compression neuropathy of the median nerve at
the wrist. Any condition that reduces the size of the car-
pal tunnel or increases the volume of its content may
cause compression of the median nerve. In the majority
of cases the cause of CTS is unknown, referred to as idio-
pathic CTS. However, there are numerous medical con-
ditions associated with CTS, such as diabetes mellitus,
thyroid disease, rheumatoid arthritis and pregnancy. [1]
The prevalence of CTS in the Netherlands was found to
be 0.6% in men and 9.2% in women (age 25–74 years).
[2] The symptoms of CTS include pain, paraesthesias
and hypoesthesias in the hand, in the area innervated by
the median nerve, and often occur or worsen during the
night or early morning, waking the patient up. Further-
more, there may also be loss of sensibility and strength,
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life and work. The clinical diagnosis of CTS can be con-
firmed by electrodiagnostic studies, which have been
found to be highly sensitive (49% to 84%) and specific
(95% or greater). [3] Clinical tests (e.g. assessing thenar
atrophy, performing provocative tests, Semmes-Wein-
stein monofilament testing) have been shown to have lit-
tle diagnostic value, but are nevertheless still widely
used. [4]
For the treatment of CTS, several conservative and surgi-
cal options are available. The most commonly used con-
servative treatment options are wrist splinting, injection
of corticosteroids into the carpal tunnel, non-steroidal
anti-inflammatory drugs (NSAIDs), systemic steroids,
pyridoxine (vitamin B6) and diuretics. [5,6] However,
there is only limited evidence of the efficacy of any of
these conservative treatment options. [7] The (methodo-
logical) limitations observed in RCTs on conservative
treatment options were prognostic inequalities between
the study groups at baseline, small sample sizes (all less
than 25 patients per treatment group), unacceptably
high drop-out/loss to follow-up rates and absence of a
long-term follow-up measurement. No RCTs were found
in which wrist splints were compared with other con-
servative treatment options, placebo or no treatment at
all, but some non-randomized and uncontrolled studies
concerning wrist splints have been published. [8–10]
Also a study comparing the effects of night-only to full-
time splint wear instructions has recently been pub-
lished. [11]
Surgical treatment options consist of sectioning the
transverse carpal ligament, resulting in an increased ca-
nal volume [12] and/or widening the bony carpal arch,
[13] thereby reducing the pressure on the median nerve.
[14] There are several surgical techniques available, but
standard open carpal tunnel release (OCTR) seems to of-
fer similar relief from CTS symptoms in the short and
long-term, compared to OCTR with a new incision tech-
nique, OCTR adding epineurotomy or internal neuroly-
sis, or endoscopic carpal tunnel release. [15] The most
prevalent (methodological) shortcomings observed in
RCTs on surgical techniques were the performance of
only short-term outcome measurements or only long-
term outcome measurements (not both), small sample
sizes (half of the studies included less than 25 patients
per treatment group) and inadequate data-presentation
(e.g. p-values instead of measures of variability).
When reviewing the literature, only 1 small-scale RCT
was found that compared conservative treatment (plas-
ter-of-paris splinting for 1 month) with surgery (OCTR).
[16] However, the trial provided no information on com-
parability of the groups at baseline, co-interventions,
compliance with the therapy or blinding of the outcome
assessor. Furthermore, only 1 follow-up measurement
was performed after 1 year, showing that all 10 patients
who were treated surgically had complete relief from
symptoms while 2 out of 10 patients who were treated
with a wrist splint had temporary relief.
There is no consensus with regard to the choice of initial
treatment for CTS. The American Academy of Neurology
advises non-invasive treatment first, i.e. wrist splints,
modification of activities, NSAIDs or diuretics, and using
invasive steroid injections or OCTR only if non-invasive
treatment have turned out to be ineffective. [17] Howev-
er, in the Netherlands 39% of the neurologists prefer
OCTR as the initial treatment for CTS, 40% prefer con-
servative measures (26% wrist splints), and 21% have no
preference. [6] In the United Kingdom, 47% of the rheu-
matologists frequently choose wrist splints and 53%
choose surgery as the initial treatment for CTS. [5]
Advocates of early surgery refer to its safety and effec-
tiveness in electrophysiologically confirmed cases with
no underlying reversible disorder. [18] In addition, they
point out that conservative therapy generally offers only
temporary symptom relief, and that surgery is unneces-
sarily delayed, causing further damage to the median
nerve. Advocates of initial conservative management of
CTS, however, refer to the potential benefits and safety of
conservative treatment options and the potential compli-
cations of surgery. [19]
In summary, there is no consensus on the preferred ini-
tial treatment for CTS, due to insufficient scientific evi-
dence for the efficacy of conservative treatment options,
and for the relative efficacy of these measures compared
with surgery. Therefore it was decided to conduct a prop-
erly designed RCT, comparing splinting and early sur-
gery, including a sufficient number of patients and an
adequate follow-up.
The main objective of this randomized clinical trial is to
determine the short and long-term efficacy of splinting
compared with early surgery in relieving CTS symptoms.
A second objective is to assess from a societal perspective
the cost-effectiveness of these treatment options.
Methods
The study is designed as a multicenter RCT. The Medical
Ethics Committees of the 13 participating hospitals ap-
proved the study protocol.
Study population
Patients with clinically suspected CTS referred to one of
the participating neurologists, are eligible for participa-
tion in the study if they meet the selection criteria. Pa-Page 2 of 7
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or hypoesthesias in the hand, in the area innervated by
the median nerve. The clinical diagnosis of CTS has to be
confirmed by electrodiagnostic studies, the methods of
which are described below. Furthermore, patients have
to be 18 years or older and able to complete written ques-
tionnaires (in Dutch). Patients are excluded from the
study if: 1) they have already been treated with a wrist
splint or have had previous carpal tunnel release; 2) they
have a history of wrist or median nerve injury from trau-
ma (e.g. contusion, fractures) or prior surgery on the
wrist; 3) they have a history suggesting underlying caus-
es of CTS, such as diabetes mellitus, thyroid disease,
rheumatoid arthritis, chronic renal failure treated by he-
modialysis, space-occupying lesions in the volar wrist ar-
ea, anatomic abnormalities of the wrist or hand,
pregnancy or lactation; 4) they have clinical signs or
symptoms, or electrodiagnostic studies suggesting con-
ditions that could mimic CTS or interfere with its valida-
tion, such as cervical radiculopathy, brachial plexopathy,
thoracic outlet syndrome, pronator teres syndrome, ul-
nar neuropathy, polyneuropathy, Raynaud's disease or
sympathetic dystrophy; 5) there is severe thenar muscle
atrophy. These inclusion and exclusion criteria are de-
signed to select a relatively homogeneous group of pa-
tients with idiopathic CTS, suitable for both splinting
and surgery.
Patients who are eligible for participation are informed
about the trial by the neurologist. If they show interest,
they receive written information about the trial and an
appointment is made with the research assistant, who
explains again the aim of the study and the implications
of participation. A research physiotherapist checks again
on all inclusion and exclusion criteria. Patient who meet
the selection criteria and are willing to participate must
complete the informed consent procedure by signing an
informed consent form.
Subsequently, an assessment is made of baseline values
of outcome measures and potential prognostic indica-
tors, such as age, gender, bilateral symptoms, dominant
side most severely affected, duration of symptoms and
preference of the patient for splinting or surgery. For all
CTS patients who are not eligible or not interested in par-
ticipation, the reasons for not non-participation are re-
corded by the neurologist or the research
physiotherapist, together with data on age, gender, dura-
tion of symptoms and prescribed treatment.
Electrodiagnostic confirmation of CTS
According to the guidelines of the American Association
of Electrodiagnostic Medicine,[3] the following protocol
is adopted: [20] Skin temperature is measured prior to
testing, and hands with a temperature of less than 32°C
are warmed. [21] Both hands are tested. Sensory and mo-
tor nerve conduction is studied, using surface electrodes
for stimulating and recording. Latencies are measured
from the stimulus onset to the initial negative response,
and amplitudes are measured from baseline to negative
peak. The sensory nerve action potentials are recorded
antidromically with ring electrodes around the proximal
(active) and distal (reference) interphalangeal joints.
The ground electrode is attached to the distal region of
the wrist. Median nerve sensory conduction velocity
(SNCV) is measured from the wrist to the index and ring
fingers. Ulnar nerve sensory conduction is measured
from the wrist to the ring finger. The distances between
the median and ulnar stimulation sides at the wrist and
the recording electrodes on the ring finger are equal. The
compound muscle action potential is recorded from the
thenar eminence with the active recording electrode
placed over the abductor pollicis brevis (APB) muscle
belly. The reference electrode is placed over the APB ten-
don. Median nerve distal motor latency (DML) is meas-
ured with stimulating and recording cathodes 7 cm
apart. Median motor nerve conduction velocity is meas-
ured in the forearm. Supramaximal stimulation is deliv-
ered to the elbow and wrist.
The electrodiagnostic criteria used to confirm the clinical
diagnosis of carpal tunnel syndrome are: 1) SNCV (index
finger) ≤ 41.9 meters/second (m/s) in patients < 55 years
or ≤ 37.3 m/s in patients ≥ 55 years, or distal sensory la-
tency (DSL) (index finger) ≥ 3.5 milliseconds (ms)[22],
or 2) median-ulnar DSL difference (ring finger) > 0.4
ms[23], or 3) DML ≥ 4.34 ms. [22]
Treatment allocation
Patients are randomly allocated to either splinting or
surgery. If bilateral symptoms are present, the hand with
the most severe symptoms, according to the patient, is
treated. A randomizationlist is prepared for each partic-
ipating hospital. Permuted blocks of 4 patients are made
to ensure near-equal distribution of patients over the two
treatment groups in each hospital (i.e. after every 4 pa-
tients the number of patients allocated to splinting is
equal to the number of patients allocated to surgery).
[24] The random sequence of the permuted blocks is
generated by using random number tables. The principle
investigator (AG), who is not involved in the selection of
patients, prepared coded, sealed, opaque envelopes con-
taining the treatment allocation. [25] After the baseline
assessment, the next envelope for the hospital concerned
is handed over to the patient by the research assistant,
thus the research physiotherapist remains blinded for
the allocation of treatment. After the patient has opened
the envelope, appointments for the allocated treatment,
either splinting or surgery, are made to ensure that thePage 3 of 7
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tion.
Blinding
Obviously, the patients cannot be blinded for the allocat-
ed treatment. Therefore, blinding of most of the outcome
measurements is not possible, due to the fact that mainly
self-reported outcomes are used. Similarly, the care-pro-
viders cannot be blinded, but they are not involved in the
outcome measurements. However, the research physio-
therapist who scores the overall severity of CTS com-
plaints after history-taking and a physical examination is
not informed about the allocated treatment. In order to
optimize blinding, the patients are asked immediately
before their visits not to reveal any information regard-
ing their treatment to the research physiotherapist. Fur-
thermore, before each examination the research
assistant sticks a plaster over the wrist and palm of all pa-
tients to conceal a potential operation scar. The success
of blinding is evaluated after each examination.
Treatments
For patients allocated to splinting, the research assistant
makes an appointment with a plaster technician, an oc-
cupational therapist or a home-care store, depending on
the usual procedures in the hospital. The splint immobi-
lizes the wrist in a neutral position in order to avoid flex-
ion or extension of the wrist, which increases carpal
tunnel pressure. [26] Depending on the hospital proce-
dures, it can be a custom-made splint (made of soft-cast)
or a prefabricated splint (trademark Tricodur), which
contains a metal strip that can be adjusted to immobilize
the wrist in a neutral position. There are no standard
prescription guidelines for wearing splints, but for this
study the patients are instructed to wear the splint dur-
ing the night for at least 6 weeks, and during the day only
if they wish to. The reason for this is that symptoms are
often worse at night and also because compliance at
night is higher than during the day [13] probably because
splinting can interfere with the activities of daily living.
The period of 6 weeks is chosen mainly because this pe-
riod is generally used in the participating hospitals. No
other types of therapy are permitted during these 6
weeks, except twice daily 250–500 mg Naproxen pre-
scribed by the neurologist for pain relief, if necessary. Pa-
tients are instructed to perform gentle range-of-motion
exercises to prevent stiffness of the wrist and fingers.
There are no work or activity restrictions for the patients.
After 6 weeks the neurologist and patient together deter-
mine whether any further treatment (continuing with
the splint, other conservative treatment options or sur-
gery) is necessary.
For patients allocated to early surgery, the research as-
sistant makes an appointment with a general surgeon,
neurosurgeon, plastic surgeon or orthopedic surgeon,
depending on the usual procedures in the hospital, for an
outpatient OCTR to be performed within 4 weeks after
randomization. Before surgery, no other types of treat-
ments are permitted, except twice daily 250–500 mg
Naproxen, prescribed by the neurologist or surgeon for
pain relief, if necessary. Patients are operated or under
regional anesthesia, using a pneumatic tourniquet, or
under local anesthesia. The following protocol is adopt-
ed: A skin incision is made in the palm, in line with the
middle finger, between the thenar and hypothenar emi-
nences. The superficial palmar fascia and the transverse
carpal ligament are divided longitudinally. Neither syn-
ovectomy nor neurolysis is performed. The skin is closed
in one single layer. A pressure dressing is applied imme-
diately after the operation and removed the next day.
Stitches are removed after 2 weeks. The patient is in-
structed to perform post-operative active range-of-mo-
tion exercises and encouraged to use the hand as
tolerated. No absolute period off sickness absenteeism is
recommended.
Outcome assessment
Although there is no consensus on which outcome meas-
ures should be used for evaluating treatment effects in
patients with CTS, outcomes related to symptoms are
considered to be the most relevant for the patients. [27]
Primary outcome measures
1. General improvement, scored by the patient on a 6-
point ordinal transition scale, ranging from 'completely
recovered' to 'much worse'. [28] To calculate success
rates, this scale is dichotomized as 'improved' (complete-
ly recovered or much improved) and 'not improved'
(slightly improved, no change, slightly worse, much
worse). If patients indicate that the symptoms have im-
proved, the date of improvement is recorded, to enable
the calculation of time (from randomization) to recovery.
2. The number of nights that the patient awoke, due to
the symptoms, during the past week.
3. The severity of the most important symptoms. At base-
line, assisted by the research physiotherapist the pa-
tients selects the complaint that he or she considers to be
the most important, e.g. paraesthesias when holding the
telephone. [29] A list of possible complaints is offered to
provide suggestions, but the patient is also allowed to se-
lect a complaint that is not on the list. The severity of this
main complaint, pain, paraesthesias and hypoesthesias
at night and during the day, during the past week are
scored by the patient on an 11-point numerical rating
scale, ranging from 0 'no symptoms' to 10 'very severe
symptoms'.Page 4 of 7
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1. The patients are asked to indicate their level of satis-
faction with the results of the treatment(s) they received
on an 11-point numerical rating scale, ranging from 0
'very unsatisfied' to 10 'completely satisfied'. [30]
2. The patients record the use of pain medication for the
symptoms during the past week (yes/no). The use of an-
algesics is considered to be an indication of the severity
of pain.
3. The severity of symptoms and functional status are as-
sessed by means of a self-administered questionnaire,
containing two scales. [31] The Symptom Severity Scale
consists of 11 questions about the severity, frequency and
duration of symptoms (pain, paraesthesias and hy-
poesthesias at night and during the day, weakness, diffi-
culty with gripping small objects) experienced during the
past 2 weeks. Items are rated from 1 (mildest) to 5 (most
severe), and the overall symptom-severity score is calcu-
lated as the mean score of all 11 items. The Functional
Status Scale consists of 8 items concerning difficulties in
performing various activities (writing, buttoning, hold-
ing a book, gripping the telephone, opening jars, per-
forming household chores, carrying a grocery bag,
bathing and dressing) during the past 2 weeks. The over-
all score for functional status is calculated as the mean of
the individual scores on the 8 items ranging from 1 (no
difficulty) to 5 (cannot perform activity at all). Items that
are not applicable are not included in the calculation of
the overall score. Therefore a response category (0) was
added, indicating that an activity is never performed
with the hand studied in the trial (e.g. writing). Both
scales are reported to be reproducible, internally consist-
ent, valid and responsive to clinical change. [31] This
study uses the Dutch version of the questionnaire, which
has already been used in an RCT on the surgical treat-
ment of CTS.[30]
4. The overall severity of CTS complaints is judged by the
research physiotherapist on an 11-point numerical rating
scale, ranging from 0 'no complaints' to 10 'very severe
complaints', after standardized history-taking and phys-
ical examination. [29] To minimize inter-observer varia-
tion the research physiotherapists are trained in
performing the measurements in a standardized way.
The history-taking includes type, timing and location of
complaints, and difficulties with performing the activi-
ties of daily life, hobbies and sports during the past week.
The physical examination includes: a) assessing thenar
atrophy (graded as none, mild or severe, based on the
bulk of the abductor pollicis brevis muscle); [32] b) per-
forming provocative tests: Tinel's percussion test, Pha-
len's wrist flexion test, wrist extension test, and the
combined wrist flexion and carpal compression test
(scored positive if symptoms are produced or exaggerat-
ed); [33] c) manual muscle-testing of the abductor polli-
cis brevis and opponens pollicis (graded from 0 to 5,
according to the criteria of the American Orthopedic As-
sociation); d) measuring maximum grip strength with a
Jamar hand-held dynamometer and maximum tip and
key pinch strength with a Jamar pinch gauge, both in kil-
ograms, calculating the mean of 3 attempts; [34] and e)
performing Semmes-Weinstein monofilament testing on
the thenar eminence, index and middle finger (recording
the lightest monofilament that a patient can feel). [33]
5. Results of electrodiagnostic studies. These studies are
performed according to the previously described proto-
col that is used to confirm the clinical diagnosis of CTS.
Other outcome measures
1. Patients are asked to record any treatment that they
have received (e.g. wrist splint, surgery, injection with
corticosteroids). To measure compliance with wrist
splinting, patients have to rate the mean number of
nights and days per week that they have been wearing the
splint. The treating physicians are also asked to record
any treatment they have prescribed for the patient on a
standard form.
2. Adverse effects that are ascribed to the therapy (e.g.
stiffness of the wrist or fingers, wound infection, hae-
matoma, painful scar) are recorded by the patient and by
the treating physicians.
3. Direct and indirect costs will be evaluated with diaries
that have to be kept up to date weekly by the patients.
[35] Patients record their visits to health care providers,
use of (prescribed) medication, household help and time
lost from paid or unpaid work. The consequences of CTS
complaints for paid or unpaid work are also evaluated by
means of a personal interview by the research assistant,
using the Health and Labor Questionnaire. [36] To com-
pare the results of the cost-effectiveness analysis with
other conditions, general health status is measured ac-
cording to the standard Dutch versions of the Medical
Outcomes Study 36-item Short-Form Health Survey
(SF-36) [37] and the EuroQol.[38]
4. To evaluate the success of blinding, the research phys-
iotherapist is asked to guess the allocated treatment after
each examination, and to state the level of certainty (0–
10) and reasons for this assumption. [28]
In order to study short and long-term treatment effects,
data are collected in the hospital at baseline and at 3, 6
and 12 months after randomization. Additional postal
questionnaires are sent to the patients in the months that
they do not visit the hospital (1, 2, 4, 5, 7, 8, 9, 10 and 11Page 5 of 7
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randomization. Table 1 gives an overview of the data-col-
lection: see Additional file 1: [table 1
(biomedcentral_revised)]
When bilateral symptoms are present, some outcome
measures (waking up at night, severity pain, paraesthe-
sias and hypoesthesias at night and during the day, use of
pain medication and treatment received) are also record-
ed for the hand not studied in the trial, at baseline and 3,
6, 12 and 18 months after randomization.
Sample size
A relative difference of 50% or more in median time to
recovery is considered to be clinically relevant. This
gives, for example, a median time to recovery of 3
months for surgery and 4.5 months for splinting. To de-
tect this difference in a survival-analysis with a signifi-
cance level (alpha) of 5% (2-sided) and a power (1-beta)
of 80%, 85 patients per treatment group are needed. To
ensure the inclusion of 190 patients, 13 hospitals are par-
ticipating in the study.
Statistical analysis
To determine whether randomization has been success-
ful, prognostic similarity between the treatment groups
is assessed at baseline for potential prognostic indicators
and baseline values of outcome measures.
The outcome measurements at 1 month, 3, 6, 12 and 18
months are considered to be the most important. There-
fore, the groups are primarily compared at these points
in time. Differences in success rates and use of pain med-
ication between the treatment groups are calculated, to-
gether with 95% confidence intervals. Survival-analysis
is used to calculate differences in median time to recov-
ery. All other outcomes are analyzed as continuous vari-
ables, and differences between the baseline
measurement and each follow-up measurement (change
score) are calculated for each patient separately. Subse-
quently, differences in mean change scores between the
treatment groups are calculated, together with 95% con-
fidence intervals. Multivariate analyses are performed to
examine the influence of differences between the groups
at baseline. All the analyses are performed according to
the intention-to-treat principle. [39] In addition, alter-
native analyses are conducted, comparing patients in the
splint group who received additional surgery with pa-
tients in this group who did not receive this extra treat-
ment.
Finally, exploratory analyses are conducted to investi-
gate whether the treatment effect (success rate and mean
improvement in severity of the main complaint) after 3
months varies in specific subgroups of patients: age ≤ 49
years versus > 49 years, male versus female, duration of
symptoms ≤ 50 weeks versus > 50 weeks, non-dominant
versus dominant side affected, unilateral versus bilateral
CTS complaints, no previous episodes versus previous
episodes of CTS complaints, preference for surgery ver-
sus splinting versus no preference, baseline severity of
the main complaint ≤ 7 versus > 7. Using logistic regres-
sion for success rate and linear regression for severity of
the main complaint, each prognostic indicator is checked
for interaction with treatment. If the interaction term is
significant, a stratified analysis will be performed.
All patients who withdraw from the study are included in
the analysis until the time of withdrawal, after which the
group mean (continues outcomes) is used to impute the
missing data. Similarly, occasional missing values are
substituted by group means. For all comparisons, a p-
value of 0.05 or less is considered to indicate statistical
significance (two-sided).
Conclusions
In this article the rationale and design of an RCT on the
efficacy of splinting compared with early surgery for CTS
is discussed. The objective of this study is to provide sci-
entific evidence for the choice of the initial treatment for
CTS. The intended size of the study population is suffi-
ciently large to detect clinically important treatment dif-
ferences, and the follow-up period is long enough to
study both short and long-term effects. The design of this
study might provide guidance for other (randomized)
studies on CTS or neurological ailments in general. The
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